The following trials provide information to treat various types of cancer and infectious disease, both for ongoing and completed clinical trials. For more information on our oncology therapy area please click here or for our infection therapy area please click here.
- collapse Phase I/II randomised, double- blind, multi-centre study to assess the efficacy of AZD2281 when given in combination with paclitaxel in the 1st or 2nd line treatment of patients with metastatic Triple Negative Breast Cancer
- collapse Open, Non-randomised, Single centre Phase I study to assess the metabolism, excretion and pharmacokinetics of a single oral 100mg dose of C-14-KU-0059436 in patients with Advanced or Metastatic solid tumours refractory to standard treatments
- collapse A phase II, open-label, non comparative, international, multicentre study to assess the efficacy and safety of KU-0059436 given orally twice daily in patients with advanced BRCA-1 or BRCA-2 associated ovarian cancer
- collapse A Phase II open-label, non-comparative, international, multicentre study to assess the efficacy and safety of KU-0059436 given orally twice daily in patients with advanced BRCA1- or BRCA2-associated breast cancer
- collapse A Phase I, Open-Label, Study of the Safety and Tolerability of KU-0059436 and Topotecan in the Treatment of Patients With Advanced Solid Tumours
- collapse A Phase I, Open-Label, Study of the Safety and Tolerability of KU-0059436 and Dacarbazine in the Treatment of Patients with Advanced Melanoma who have not previously received systemic chemotherapy.
- collapse A Phase I, Pharmacokinetic and Biological Evaluation of a Small Molecule Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP-1), KU-0059436, in Patients with Advanced Tumours.
- collapse A Phase I, open-label, dose escalation study to assess the safety and tolerability of AZD2281 following single and multiple oral doses in patients in Japan with advanced solid malignancies.
- collapse Exploratory Open-Label, Non-randomised, Single Centre Methodology Study Comparing DCE-CT and DCE-MRI as Markers of Changes in Vascular Activity Mediated by a Positive Control Agent [Cediranib (Recentin; AZD2171), a Potent Inhibitor of VEGF-driven Angiogenesis] in Patients with Advanced Solid Tumour
- collapse A Multicentre, Randomised, Double Blind, Placebo Controlled Study on the Use of Prophylactic Meropenem Therapy in Subjects with Severe Acute Necrotizing Pancreatitis.
